Amgen wins patent infringement case against Sanofi/Regeneron (Praluent)

A federal judge rejected the motion related to a patent infringement case between Amgen—which obtained a favorable verdict last March—and Sanofi/Regeneron, Reuters reported. Indeed, in October 2014 Amgen sought to stop sales of Praluent, a drug from the class of PCSK9 inhibitors intended to treat hypercholesterolemia, since it allegedly violated patents on Amgen’s Repatha. A jury ruled in favor of Amgen in March. Following that verdict, Sanofi and Regeneron appealed and sought a new trial. However, the judge denied that motion. Damages have yet to be set, and the judge has not decided yet whether to block Praluent’s commercialization.
(Source Seeking Alpha)